Novome Biotechnologies is a biotechnology company focused on engineering defined activities into the human gut microbiota to treat chronic diseases. The company has developed a platform for controlled colonization of the gut with engineered bacteria, enabling first-in-class living therapeutics known as Genetically Engineered Microbial Medicines (GEMMs). Novome's lead preclinical program targets hyperoxaluria, a condition characterized by excessive oxalate levels.

Key achievements include the development of the first-ever platform for controlled gut colonization with engineered bacteria. Novome's innovative approach has the potential to revolutionize chronic disease treatment by leveraging the human microbiome. The company's impact is significant in the field of living therapeutics, positioning it as a pioneer in gut microbiota engineering.